key: cord-0996786-2xbt920p authors: De Luca, Daniele; Autilio, Chiara title: Strategies to protect surfactant and enhance its activity date: 2021-08-05 journal: Biomed J DOI: 10.1016/j.bj.2021.07.011 sha: f28767c066a7b816bcf3442667cf390f9febcb90 doc_id: 996786 cord_uid: 2xbt920p The knowledge about surfactant biology is now deeper and recent research has allowed to clarify its role in several human lung disorders. The balance between surfactant production and consumption is better known and the same applies to their regulatory mechanisms. This has allowed to hypothesize and investigate several new and original strategies to protect surfactant and enhance its activity. These interventions are potentially useful for several disorders and particularly for acute respiratory distress syndrome. We here highlight the mechanisms regulating surfactant consumption, encompassing surfactant catabolism but also surfactant injury due to other mechanisms, in a physiopathology-driven fashion. We then analyze each corresponding strategy to protect surfactant and enhance its activity. Some of these strategies are more advanced in terms of research & development pathway, some others are still investigational, but all are promising and deserve a joint effort from clinical-academic researchers and the industry. these can cause quantitative and qualitative surfactant dysfunction. In normal conditions, surfactant production and consumption are well balanced and ensure a low alveolar surface tension (<5 mN/m) and the absence of relevant lung tissue inflammation. RDS and pulmonary alveolar proteinosis (PAP) are characterized by decreased production and consumption, respectively [2, 5] . Thus, In RDS decreased production leads to low surfactant levels, whereas in PAP decreased consumption leads to high surfactant levels. Acute respiratory distress syndrome in adult (ARDS) [6] , pediatric (PARDS) [7] and neonatal (NARDS) [8] patients are more complex disorders where surfactant is variously damaged by an increased catabolism and/or various molecular injuries and this can also be associated with a relatively insufficient production in preterm neonates [3, 9] . The biological and biochemical agents responsible for surfactant catabolism and molecular injury are numerous and can interact between them. We are now aware of these mechanisms and there are promising molecules and techniques holding potential to protect surfactant and preserve its functions during increased catabolism or in presence of surfactant-injuring agents. However, it is crucial to increase our knowledge about the interplay between surfactant catabolism and surfactant-injuring agents to provide more efficient surfactant protection strategies. Here we intend to briefly summarize surfactant recycling and catabolism. The former is the physiological mechanism of reuptake and substitution of surfactant phospholipids and proteins when needed [10] , while the latter may result in a pathological process when increased surfactant phospholipid or protein destruction in absence of physiological needs occur and it is elicited by some pathological triggers. Type-II pneumocytes (i.e.: the same cells responsible for surfactant production) perform both surfactant recycling and catabolism and they are responsible for most of the recycling [10] . Conversely, alveolar macrophages (the cell type involved in the inflammatory cascade) are involved in surfactant catabolism and particularly they have a predominant role during pathological situations characterized by high lung tissue inflammation [10] . Catabolism is up-regulated when increasing doses of exogenous surfactant are administered in animal models [11] , whereas it is insufficient in PAP which is caused by autoimmune or hereditary disfunction in GM-CSF signaling, leading to fewer and less active alveolar macrophages [5] . This leads to the abnormal accumulation of less functional and oxidized surfactant components in the alveolar space with a reduction in the pulmonary diffusion capacity [12] . In normal situations surfactant production and consumption are balanced, and this allows to achieve low alveolar surface tension and lack of significant lung tissue inflammation. In RDS, which is usually affecting preterm neonates, surfactant production is reduced. In patients with PAP, surfactant consumption is relatively reduced compared to its production. ARDS in adults, in pediatric (PARDS) or neonatal (NARDS) patients are disorders of various severity characterized by increased surfactant catabolism and normal primary surfactant production. NARDS may also occur in preterm neonate: in this case a relative primary surfactant deficiency can co-exist. Alveolar macrophages are the main cells producing the isotype-IIA of secretory phospholipase A2 (sPLA2-IIA) [13] . The activity of this enzyme is increased by GM-CSF treatment [14] and there is a significant correlation between GM-CSF and sPLA2-IIA expression and activity [15] . From a molecular point of view, surfactant lipid recycling and catabolism are due to several distinct mechanisms that may involve various surfactant components and may differentially be involved in either recycling or catabolism. For instance, by promoting membrane fragmentation [12] , surfactant protein-D and -C (SP-D and SP-C), may affect the structure and conversion of surfactant large aggregatessurface-active large aggregates of heavy density -into small aggregates. The latter are small vesicles with light density and low interfacial activity that probably may also result from breathing mechanics. Interestingly, Surfactant Protein A (SP-A) may interact with these small aggregates, favoring their uptake by type-II pneumocytes [12] . It has been suggested that SP-D and SP-C may also play a role in macrophages clearance of surfactant phospholipid and cholesterol, under both physiological conditions and aging [12] . A further mechanism that also regulates both surfactant phospholipid recycling and catabolism involves sPLA2 enzymes, which hydrolyze phospholipid by detaching a free fatty acid from their sn-2 position. This hydrolysis has several consequences on the biophysical and biological function of surfactant. In fact, sPLA2 hydrolysis is directly proportional to the alveolar surface tension [16] and, as consequence, inversely proportional to lung compliance and gas exchange function [17, 18] . PLA2 hydrolysis is a complex process as various enzyme subtypes are expressed in human lung tissue and they have different phospholipid substrate specificity although they can all variously contribute to the impairment of surfactant biophysical activity [19, 20] . Beyond these biophysical consequences, sPLA2 hydrolysis also leads to the production of free fatty acids, especially arachidonic acid (C 20 H 32 O 2 , 20:4), making it available for the further steps of the inflammatory cascade [8] . Therefore, sPLA2 enzymes represent a crucial dual target since, from one side, they can impair surfactant function, and, from the other side, they may increase lung tissue inflammation which, in its turn, injures surfactant. This represents the socalled "ARDS vicious cycle" where surfactant catabolism and inflammation perpetuate each other, since pro-inflammatory cytokines (notably tumor necrosis factor-a and GM-CSF [21, 22] ) increase the production of sPLA2-IIA which again catabolizes surfactant phospholipids [13] . As a consequence, sPLA2 activity in broncho-alveolar lavage samples from ARDS patients also shows correlation with relevant clinical outcomes [18,23e25] . The role of sPLA2 enzymes is not only crucial in surfactant recycling and catabolism but there are also important interplays with several proteins. These include the sPLA2 receptor which would allow several effects independent from hydrolysis [26] , and other enzymes such as cytosolic phospholipases [27] depicting a complex interactome, whose description is out of our scopes. We will however detail the main mechanisms modulating sPLA2 actions as these are the basis for possible surfactant protection strategies. Surfactant protein-A (SP-A) is a hydrophilic surfactant protein with important anti-infectious and anti-inflammatory properties. In details, the SP-A2 isoform is involved in anti-inflammatory and immunomodulatory properties, whereas SP-A1 contributes more to lipid aggregation and helps in both adsorption and spreading of massive amounts of surfactant material at the air-liquid interface [12] . Notably, SP-A is able to decrease sPLA2-IIA expression but also to inhibit its activity by a protein-to-protein calcium dependent interaction [21, 28] . SP-A represents the most potent agent to this end, but it is not the only one, since a negatively charged phospholipid, the dioleoylphosphatidylglycerol (DOPG; C 42 H 79 O 10 P, PG 36:2) is also able to downregulate sPLA2-IIA expression [21, 22] . Compared to SP-A, that also plays an effect on surfactant biophysical function (by facilitating surfactant adsorption and spreading), DOPG is a minor surfactant constituent with no effect on surface tension. However both these molecules are important as negative feedback agents modulating the role of sPLA2 [13] . Other sPLA2-modulating agents are surfactant protein-B (SP-B) which seems to reduce surfactant hydrolysis caused by both sPLA2 subtype-IB and -IIA: this seems to be related to a lower availability of lipid substrate for the catalytic site of sPLA2 enzymes, due to SP-B creating packed phospholipid layers [29] . Interestingly, SP-B seems also to be increased as acute-phase protein during pulmonary infections [30] , thus its anti-sPLA2 effect may have a protective role when the inflammation is too much extended. Club cell secretory protein (CCSP) is produced in the airway epithelium and has multiform potent anti-inflammatory properties [31] . Particularly, CCSP interacts with sPLA2 enzymes by blocking neutrophil influx and fibroblast migration mediated by sPLA2 [32, 33] and seems to be involved in the mitigation of ventilator-induced lung injury [34, 35] and the mechanisms of ARDS in patients of any age [25,36e40] . As sPLA2 activity is extremely important to guarantee a balance between surfactant production and consumption, it is not surprising that several molecules may modulate sPLA2 pathway, guaranteeing a certain redundancy. There are several agents able to injure surfactant through molecular mechanisms unrelated to surfactant catabolism, but still able to cause relevant quantitative and qualitative surfactant dysfunction. Table 1 lists the main surfactantinjuring agents playing a role in human diseases: the biochemical mechanisms of these injuries are numerous [9,41e56] . Blood proteins may compete with surfactant aggregates, reducing surfactant adsorption (e.g. albumin) or change surfactant fluidity/structure (e.g. C-Reactive Protein), significantly impacting on its biophysical function. Moreover, upon pathological mechanisms, the presence of proteins which are not normally found in the alveolar space may also affect other biological functions by interacting with surfactant-proteins. On top of this effect, hemoglobin may contribute to the inflammation processes, causing protein and lipid oxidation. The latter is also a transversal mechanism, triggered by the rise in reactive species of oxygen that may happen under several circumstances and negatively influence surfactant function. Cholesterol is an important surfactant component but, when it is increased, it worsen surfactant b i o m e d i c a l j o u r n a l 4 4 ( 2 0 2 1 ) 6 5 4 e6 6 2 function, since it is a small amphiphilic molecule and makes surfactant complexes more fluid [12] . Bile acids seem to enhance the cholesterol distribution in surfactant membranes and act as co-enzyme of sPLA2, facilitating surfactant phospholipid hydrolysis and production of inflammatory mediators, including the release of free fatty acids, which may in turn change surfactant fluidity and structure. More coarse injuring agents, such as smoke, sea water, milk, food, or gastric secretion, may be aspirated and create various damages: they can modify surfactant structure or fluidity, dilute surfactant and create an osmotic injury. They can also have a direct cytopathic effect on the alveolar and airway epithelium and obstruct small airways with debris preventing the physiological diffusion of surfactant toward the upper airways via the mucociliary movement [10] . This process may contribute to surfactant recycling and help keeping small airways open. Moreover, the resulting injury may also facilitate local infections which, in turn, may contribute to the epithelium damages and increase local inflammation and oxidation, affecting both surfactant structure and activity. These mechanisms are involved in the pathogenesis of various types of ARDS in patients of diverse ages and can also be simultaneously present in each patient. This explains the pathobiological complexity of ARDS: this syndrome, although appears with a common clinical trait, may have different underlying mechanisms of injury and the prevalent one may vary. Therefore, it is important to recognize different ARDS subtypes according to its pathobiology, as this may help to choose one strategy to protect surfactant over the others: several promising therapies have failed because they were trialed in mixed and inhomogeneous populations of patients who had different physiopathology context [3] . Unfortunately, recognizing the physiopathology behind the different subtypes of ARDS is not yet totally and easily possible, as these mechanisms of injury can be overlapped and they are not always measurable at the bedside. However, some distinctions have been recently possible, and, for instance, we know that primary (direct) ARDS has a more evident epithelial injury and alveolar inflammation pattern, while the secondary (indirect) form of the syndrome is preferentially characterized by endothelial injury and systemic inflammation [57, 58] . A particular case is represented by neonatal bile acid pneumonia, typical of neonates born to mothers with intrahepatic cholestasis of pregnancy [59, 60] . This is relatively rare disorder that can appear as mild or severe respiratory failure caused by bile acids reaching the lung through the systemic circulation [61] . The physiopathology of bile acid pneumonia is complex and represents an example of overlap of surfactant catabolism and other types of surfactant injury. In fact, bile acids act as sPLA2 co-enzyme facilitating the enzymeesubstrate interaction [44, 62] , but they can also alter surfactant biophysical properties, changing surfactant fluidity directly or act as mediators to mobilize and transfer cholesterol into surfactant complexes [12] . Finally, bile acids also increase pro-inflammatory cytokines and seem to reduce hydrophilic surfactant protein which have antiinflammatory and immune defense roles [63, 64] . The understanding of the pathobiological pattern of surfactant injury will be crucial in the future to develop and eventually choose surfactant protection strategies. Table 1 The main agents capable to injure surfactant with mechanisms different from direct catabolism and associated human diseases. Albumin [9, 41] Change surfactant fluidity and structure Indirect (secondary) ARDS Hemoglobin [42] Increased inflammation, capillary occlusion, protein/lipid oxidation. Indirect (secondary) ARDS, Maternal blood aspiration a , Pulmonary hemorrhage a Other plasma proteins [9, 41] Change surfactant fluidity and structure, interaction with surfactant proteins Indirect (secondary) ARDS Cholesterol [43] Change surfactant fluidity Indirect (secondary) ARDS, Meconium aspiration a Bile acids [44] Change surfactant film structure and facilitate sPLA2substrate interaction, increase inflammation Neonatal bile acid pneumonia a Bile aspiration a Milk/Gastric secretions [45, 46] Change surfactant fluidity and structure, direct cytopathic damage Milk/gastric content aspiration a Inflammatory cytokines [47, 48] Epithelial injury; change surfactant fluidity and structure Indirect (secondary) or direct (primary) ARDS Free fatty acids [49] Change surfactant fluidity and structure Indirect (secondary) ARDS Water [50] Osmotic damage Dilution of surfactant Near drowning a Viral infection [51, 52] Cytolysis, direct cytopathic effect Viral pneumonia a Oxidative stress [53, 54] Protein oxidation Indirect (secondary) or direct (primary) ARDS Antigen-Antibody response [55] Cellular injury induced by alloantibodies TRALI Smoke [53, 56] Epithelial injury, susceptibility to infections, change surfactant fluidity and structure and other afore-mentioned mechanisms Possible strategies to protect surfactant There are several possible strategies to protect surfactant and enhance its activity or at least preserve it. The various strategies correspond to the different injury mechanisms described above and are represented [ Table 2 ] by several drug candidates but also by some techniques, such as whole-body hypothermia, repeated surfactant bolus or lavage with diluted surfactant solutions. These strategies act through the following mechanisms: -availability of more surface-active surfactants or catabolismresistant surfactants (for instance, by changing the phospholipid profile or adding hydrophilic proteins to surfactant composition or using controlled whole-body hypothermia); -surfactant protection using direct sPLA2-inhibitors competing for the phospholipid substrate (for instance, indolic inhibitors such as varespladib); -reduction of inflammation using steroids, CCSP, hydrophilic surfactant proteins or interleukin inhibitors that, in some cases, might also reduce sPLA2 expression (some of these agents may be vehicled by surfactant itself and reach the alveoli in high concentration). Similar results might be obtained using controlled whole-body hypothermia; -reduction of oxidation using antioxidant agents (some of these agents may be vehicled by surfactant itself and reach the alveoli in high concentration); -administration of higher or repeated surfactant doses to overcome the inactivation and/or restore a functional phospholipid profile; -removal of injuring agents performing lung lavages with diluted surfactant solutions. These strategies vary in terms of their research and development stage. Some drugs have been clinically tested in large populations such as surfactant-vehicled budesonide in preterm neonates with RDS [93] and/or NARDS [94] or systemic steroids in adults with ARDS [95] and they only need explanatory clinical investigations to be refined. Other drugs have a very promising safety and efficacy profiles but, unfortunately, have not been tested yet for a lack of industrial interest, despite the clinical unmet need and their potential. For some others, such as surfactant protein-D [65] , the clinical research is underway, while, for anti-interleukin agents, their use for ARDS during the pandemics might allow to quickly accumulate an unexpected clinical experience [78] . There are also strategies based on techniques rather than drugs, such as the use of whole-body hypothermia, repeated surfactant dose or surfactant lavages. Controlled whole-body hypothermia can reduce lung tissue inflammation, sPLA2 expression and activity, and improve surfactant function by modifying its composition and structure [96e100]. Based on these effects, hypothermia has been efficaciously used for NARDS due to meconium aspiration [101] or for primary ARDS induced by various triggers [102, 103] . It is interesting to note that despite surfactant being used since decades a clear dose-finding study has not been performed. Clinical and pharmacodynamic data show that 200 mg/kg is the dose to be preferred in preterm neonates with RDS [104] but not much is known about the ideal dose for different types of ARDS in patients of various age. This area represents a field to be urgently explored [105] to provide an efficacious treatment for human diseases involving surfactant system. Finally, lavage with diluted surfactant has been extensively studied in neonates with primary NARDS due to meconium aspiration and seems to be efficacious in removing meconial agents able to injure surfactant [90] , but many details are still to be clarified, such as the volume, concentration, total dose, technique and timing of lavage. The same technique could theoretically be beneficial in other types of primary ARDS, but the experience is more limited. The literature regarding each of these strategies is listed in Table 2 and could be useful to guide future research steps of basic and clinical researchers. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Prof. De Luca has received research and educational grants from Chiesi Pharmaceuticals spa and ABBVIE inc. He served as lecturer for Airway Therapeutics, Chiesi Pharmaceuticals spa and ABBVIE inc. He is a scientific consultant and equity owner for OPHIREX inc. Finally, he has been member of advisory boards for Chiesi Pharmaceuticals spa, ABBVIE inc and Airway Therapeutics. These companies produce surfactants, surfactant proteins or related products, but had no role in design, preparation, review, approval of the manuscript or decision to submit it for publication. The declared conflicts are all unrelated to the present manuscript. The other author has no conflicts of interest to disclose. r e f e r e n c e s Artificial surfactant therapy in hyaline-membrane disease Personalized medicine for the management of RDS in preterm neonates Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps Neonatal respiratory diseases in the newborn infant: novel insights from stable isotope tracer studies Pulmonary alveolar proteinosis Acute respiratory distress syndrome: the Berlin Definition Pediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE) investigators; pediatric acute lung injury and sepsis investigators (PALISI) network. Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity Surfactant alteration and replacement in acute respiratory distress syndrome Pulmonary surfactant metabolism in the alveolar airspace: biogenesis, extracellular conversions, recycling Surfactant phospholipid catabolic rate is pool size dependent in mice Understanding the principle biophysics concepts of pulmonary surfactant in health and disease A role for phospholipase A2 in ARDS pathogenesis Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice Surfactant-secreted phospholipase A 2 interplay and respiratory outcome in preterm neonates Hydrolysis of surfactant-associated phosphatidylcholine by mammalian secretory phospholipases A2 Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome Cell-specific expression of group X and group V secretory phospholipases A 2 in human lung airway epithelial cells Lysophospholipid generation and phosphatidylglycerol depletion in phospholipase A(2)-mediated surfactant dysfunction Dioleylphosphatidylglycerol inhibits the expression of type II phospholipase A2 in macrophages Surfactant protein-A and phosphatidylglycerol suppress type IIA phospholipase A2 synthesis via nuclear factor-kb Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants Role of distinct phospholipases A2 and their modulators in meconium aspiration syndrome in human neonates Phospholipase A2 subclasses in acute respiratory distress syndrome Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein Aphospholipase A2 protein interaction Surfactant protein B inhibits secretory phospholipase A 2 hydrolysis of surfactant phospholipids Surfactant protein B and A concentrations are increased in neonatal pneumonia Rationale for the development of recombinant human CC10 as a therapeutic for inflammatory and fibrotic disease Pulmonary secretory phospholipase A2 in infants with respiratory distress syndrome stimulates in vitro neutrophil migration Clara cell protein (CC-16) induces a phospholipase A2-mediated inhibition of fibroblast migration in vitro Clara cell secretory protein and phospholipase A 2 activity modulate acute ventilatorinduced lung injury in mice Time and pressure dependence of transvascular Clara cell protein, albumin, and IgG transport during ventilatorinduced lung injury in mice Clara cell secretory protein modulates lung inflammatory and immune responses to respiratory syncytial virus infection Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: a preliminary study Potential role of Clara cell protein, an endogenous phospholipase A 2 inhibitor, in acute lung injury Outcome value of Clara cell protein in serum of patients with acute respiratory distress syndrome Clara cell protein as a marker of Clara cell damage and bronchoalveolar blood barrier permeability Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome The role of red blood cells and cell-free hemoglobin in the pathogenesis of ARDS Effect of cholesterol on the biophysical and physiological properties of a clinical pulmonary surfactant Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration Comparison of exogenous surfactant and positive end-expiratory pressure therapies in a model of human breast milk-induced acute lung injury in rabbits Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials Changes in subphase aggregates in rabbits injured by free fatty acid Seawater-drowning-induced acute lung injury: from molecular mechanisms to potential treatments Functional pathophysiology of SARS-CoV-2-induced acute lung injury and clinical implications Influenza virus-induced lung injury: pathogenesis and implications for treatment Functional genomics of oxidant-induced lung injury Surfactant deficiency in transient tachypnea of the newborn Transfusion-related acute lung injury treated with surfactant in a neonate Effects of smoke inhalation on surfactant phospholipids and phospholipase A2 activity in the mouse lung Acute respiratory distress syndrome Phenotypes in acute respiratory distress syndrome: moving towards precision medicine Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy Intrahepatic cholestasis of pregnancy and neonatal respiratory distress syndrome Bile acid-induced lung injury in newborn infants: a bronchoalveolar lavage fluid study Role of macrophages in bile acidinduced inflammatory response of fetal lung during maternal cholestasis The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem 18:1/18:1-Dioleoylphosphatidylglycerol prevents alveolar epithelial apoptosis and profibrotic stimulus in a neonatal piglet model of acute respiratory distress syndrome Evaluation of recombinant human SP-D in the rat premature lung model Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury Surfactant and varespladib Coadministration in stimulated rat alveolar macrophages culture Inhibitors of phospholipase A 2 and their therapeutic potential: an update on patents Inhibition of secretory phospholipase A2-induced cytokine production in human lung macrophages by budesonide Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study Surfactant plus budesonide decreases lung and systemic inflammation in mechanically ventilated preterm sheep Effects of budesonide and surfactant in preterm fetal sheep Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial The role of antirheumatics in patients with COVID-19 Nonventilatory treatments for acute lung injury and ARDS Pharmacological therapies for pediatric and neonatal ALI/ARDS: an evidence-based review Cytokine balance in the lungs of patients with acute respiratory distress syndrome Natural surfactant combined with beclomethasone decreases lung inflammation in the preterm lamb Acute respiratory distress syndrome: pharmacological treatment options in development Surfactant from neonatal to pediatric ICU: bench and bedside evidence Antioxidant strategies and respiratory disease of the preterm newborn: an update Natural surfactant combined with superoxide dismutase and catalase decreases oxidative lung injury in the preterm lamb: surfactant Plus SOD and CAT for RDS Natural surfactant combined with beclomethasone decreases oxidative lung injury in the preterm lamb: oxidative Lung Injury in the Preterm Lamb Superoxide dismutase and catalase activity in naturally derived commercial surfactants Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review Surfactant lavage therapy for meconium aspiration syndrome: a systematic review and meta-analysis A multicenter, randomized, controlled trial comparing surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS) Alternatives to systemic postnatal corticosteroids: inhaled, nebulized and intratracheal Endotracheal surfactant combined with budesonide for neonatal ARDS Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS Controlled hypothermia may improve surfactant function in asphyxiated neonates with or without meconium aspiration syndrome Effect of whole body hypothermia on inflammation and surfactant function in asphyxiated neonates Effect of cooling on lung secretory phospholipase A2 activity in vitro, ex vivo, and in vivo Molecular and biophysical mechanisms behind the enhancement of lung surfactant function during controlled therapeutic hypothermia Effect of whole body hypothermia on surfactant function when amniotic fluid is meconium stained Hypothermia and meconium aspiration syndrome: international multicenter retrospective cohort study Use of hypothermia to allow low-tidal-volume ventilation in a patient with ARDS Successful use of mild therapeutic hypothermia as compassionate treatment for severe refractory hypoxemia in COVID-19 Dosing of porcine surfactant: effect on kinetics and gas exchange in respiratory distress syndrome Carelessness about surfactant doseda cultural problem, a legal issue, or an open research question?